Conditional survival in patients with gallbladder cancer

• Published in: Ai zheng Vol. 36; no. 12; pp. 744 - 756
• Main Authors: Kim, Yi‐Jun, Kim, Kyubo
• Format: Journal Article
• Language: English
• Published: London BioMed Central 30.10.2017; BioMed Central Ltd; John Wiley & Sons, Inc; Department of Radiation Oncology,Ewha Womans University College of Medicine,1071 Anyangcheon-ro,Yangcheon-gu,Seoul 07985,Republic of Korea; BMC
• Subjects: Analysis; cancer; Cancer patients; Care and treatment; Colorectal cancer; Conditional; Conditional survival; Confidence intervals; Diagnosis; Epidemiology; Gallbladder; Gallbladder cancer; Gastric cancer; Health aspects; Histology; Marital status; Medical prognosis; Multivariate analysis; Original; Patients; Prognosis; Radiation therapy; Radiotherapy; SEER; Surgery; Surveillance; survival; Survival analysis; United States > US; Conditional survival; SEER; Gallbladder cancer
• ISSN: 1000-467X; 2523-3548; 1944-446X; 1944-446X; 2523-3548
• DOI: 10.1186/s40880-017-0252-1

Background: Conditional survival (CS) has been established as a clinically relevant prognostic factor for cancer survivors,and the CS in gallbladder (GB) cancer has not yet been fully evaluated. In this study, we evaluated the cancerspecific CS rate and cancer-specific survival (CSS) rate in patients with GB cancer at multiple time points and investigated prognostic factors which affect cancer-specific CS rate to provide more accurate survival information.Methods: Between 2004 and 2013, a total of 9760 patients with GB cancer were identified from the Surveillance,Epidemiology, and End Results (SEER) data. The 3-year cancer-specific CS rate was calculated using the covariateadjusted survival function in the Cox model for each year since diagnosis, and the results were analyzed together with the adjusted CSS rates at the same time points. Cox proportional hazards regression was performed to ascertain the individual contribution of factors associated with CSS rate at diagnosis and cancer-specific CS rates at 1, 3, and 5 years after diagnosis.Results: The adjusted 5-year CSS rate was 26.1%. The adjusted 3-year cancer-specific CS rates at 1, 2, 3, 4, and 5 years after diagnosis were 55.5, 72.2, 81.5, 86.8, and 90.5%, respectively. At the time of diagnosis, age, race, histology, grade,T, N, and M categories, surgery, radiotherapy, insurance status, and marriage status were significant prognostic factors of CSS. Five years after diagnosis, however, T and M categories were significant prognostic factors for survivors (P = 0.007 and P = 0.009, respectively), whereas surgery and radiotherapy were not. Conclusions: T and M categories were significant prognostic factors even 5 years after the initial diagnosis, whereas local treatments at the time of diagnosis were not, suggesting that patients with GB cancer at high risks might need further adjuvant therapy after primary treatments. The combined analysis of CSS and cancer-specific CS rates offered more accurate survival information for patients who have already survived a certain period of time after diagnosis.